Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …

Breast cancer, the most frequently occurring cancer in women, is a major public health
problem, with 1,384,155 estimated new cases worldwide with nearly 459,000 related …

Background Pembrolizumab monotherapy showed durable antitumour activity and
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …

Importance Among all subtypes of breast cancer, triple-negative breast cancer has a
relatively high relapse rate and poor outcome after standard treatment. Effective strategies to …

Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …

Purpose: Patients with hormone receptor–negative breast cancer generally do not benefit
from endocrine-targeted therapies. However, a subset with androgen receptor (AR) …

Triple-negative breast cancer, so called because it lacks expression of the estrogen
receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast …

Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is
associated with poor long-term outcomes compared with other breast cancer subtypes …

All three of the traditionally recognized new institutionalisms–rational choice, historical, and
sociological–have increasingly sought to 'endogenize'change, which has often meant a turn …

Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …